Clinical Research Directory
Browse clinical research sites, groups, and studies.
Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors
Sponsor: Instituto de Investigación Biomédica de Salamanca
Summary
This prospective observational study aims to assess the association between real-world use of sodium-glucose co-transporter 2 inhibitors (SGLT2i; e.g., empagliflozin, dapagliflozin) and renal function decline in adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification). The study will also validate a urinary biomarker panel for early diagnosis and monitoring of CKD progression. No investigational product is assigned, and medical practice or prescription patterns are not altered.
Official title: Diagnostic and Monitoring System for Chronic Kidney Disease Based on Urinary Biomarkers and Preventive Treatment With the SGLT2 Inhibitor Empagliflozin
Key Details
Gender
All
Age Range
16 Years - Any
Study Type
OBSERVATIONAL
Enrollment
300
Start Date
2026-01
Completion Date
2028-03
Last Updated
2026-01-16
Healthy Volunteers
No
Conditions
Interventions
Empagliflozin
Oral empagliflozin (10-25 mg daily) for 12 months
Locations (1)
Hospital Universitario de Salamanca
Salamanca, Spain